Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Acro Biomedical (ACBM) Revenue (2017 - 2022)

Acro Biomedical has reported Revenue over the past 6 years, most recently at $360000.0 for Q4 2022.

  • Quarterly results put Revenue at $360000.0 for Q4 2022, down 39.8% from a year ago — trailing twelve months through Sep 2023 was $360000.0 (down 59.84% YoY), and the annual figure for FY2022 was $658500.0, down 45.01%.
  • Revenue for Q4 2022 was $360000.0 at Acro Biomedical, up from $298500.0 in the prior quarter.
  • Over the last five years, Revenue for ACBM hit a ceiling of $2.4 million in Q3 2018 and a floor of -$826.0 in Q3 2019.
  • Median Revenue over the past 5 years was $549000.0 (2021), compared with a mean of $888347.8.
  • Biggest five-year swings in Revenue: plummeted 100.03% in 2019 and later skyrocketed 200.0% in 2022.
  • Acro Biomedical's Revenue stood at $1.4 million in 2018, then crashed by 85.71% to $193536.0 in 2019, then skyrocketed by 255.47% to $687964.0 in 2020, then dropped by 13.08% to $598000.0 in 2021, then tumbled by 39.8% to $360000.0 in 2022.
  • The last three reported values for Revenue were $360000.0 (Q4 2022), $298500.0 (Q1 2022), and $598000.0 (Q4 2021) per Business Quant data.